Who is sponsoring NCT06768970?

NCT06768970 is sponsored by Hofseth Biocare ASA.

What condition does NCT06768970 study?

NCT06768970 studies Sleep, Pollution; Exposure, Cough.

What drugs are being tested in NCT06768970?

Interventions: CARDIO® salmon oil.

What is the status of NCT06768970?

NCT06768970 is currently COMPLETED.

Last reviewed 2025-01-10 · How we verify

Investigating the Effect of Daily CARDIO® Capsules Supplementation on Improved Sleep in Healthy, Urban-Dwelling Adults

NCT06768970 NA COMPLETED

This study aims to explore the impact of supplementation with CARDIO® whole salmon oil capsules on healthy adult participants with sleep disruption related to particulate matter pollution. The trial will employ a decentralized approach enabled by modern technology and wearables to measure sleep quantity and quality. Validated patient reported outcome (PRO) measures will be employed to measure the impact on cough and the subjective assessment of sleep quality and wellbeing. After a two week run-in period, subjects will be randomized to OmeGo at either 2g or 4g daily for 8 weeks. Final assessment will be at week 10.

Details

Lead sponsor	Hofseth Biocare ASA
Phase	NA
Status	COMPLETED
Enrolment	131
Start date	Tue May 14 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Jan 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Sleep
Pollution; Exposure
Cough

Interventions

CARDIO® salmon oil

Countries

United States